BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Beta Bionics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$16.84+0.49 (+3.00%)
Close on Oct 19, 2026
- Market cap
- $750.14M
- P/E (TTM)
- –
- Dividend yield
- –
Beta Bionics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Market Cap | $757.63M | $230.55M |
| Enterprise Value | $577.14M | $202.97M |
| PS Ratio | 6.37 | 3.10 |
| PB Ratio | 2.96 | 3.04 |
| P/TBV Ratio | 2.96 | 4.43 |
Enterprise value
| Measure | Beta Bionics | Industry median |
|---|---|---|
| EV / Sales | 4.85 | 2.91 |
Income (trailing twelve months)
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Revenue | $119.01M | $102.39M |
| Gross Profit | $69.40M | $60.36M |
| Operating Income | -$83.02M | -$4.31M |
| Net Income | -$72.97M | -$6.57M |
| EBITDA | -$83.02M | -$1.98M |
| EPS (Diluted) | -$1.65 | -$0.08 |
Margins
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Gross Margin | 58.3% | 55.2% |
| Operating Margin | -69.8% | -6.04% |
| Profit Margin | -61.3% | -10.5% |
| EBITDA Margin | -69.8% | -2.67% |
| FCF Margin | -51.6% | 0.02% |
Returns
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -26.2% | -18.2% |
| Return on Assets (ROA) | -23.5% | -13.3% |
| Return on Invested Capital (ROIC) | -102.6% | -3.69% |
| Return on Capital Employed (ROCE) | -31.2% | -9.07% |
Growth
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 52.5% | 8.85% |
Balance sheet
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $180.49M | $36.66M |
| Net Cash (Debt) | $180.49M | $3.92M |
| Net Cash Per Share | $4.01 | $0.28 |
| Equity (Book Value) | $256.37M | $55.33M |
| Book Value Per Share | $5.70 | $2.87 |
| Tangible Book Value | $256.37M | $10.79M |
| Working Capital | $205.02M | $56.72M |
Financial position
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Current Ratio | 8.88 | 2.48 |
| Quick Ratio | 7.63 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Operating Cash Flow | -$55.81M | -$566.22K |
| Capital Expenditures | -$5.60M | -$3.69M |
| Free Cash Flow | -$61.41M | -$696.00K |
| FCF Per Share | -$1.36 | -$0.02 |
Efficiency
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Asset Turnover | 0.38 | 0.58 |
| Inventory Turnover | 2.41 | 2.21 |
| Revenue Per Employee | $283.36K | $322.92K |
| Profits Per Employee | -$173.75K | -$51.88K |
| Employee Count | 420 | 185 |
Dividends and yields
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Earnings Yield | -9.63% | -6.88% |
| FCF Yield | -8.11% | -0.45% |
Shares
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Shares Outstanding | 44,989,700 | 44,302,700 |
| Shares Change (YoY) | 102.3% | 3.36% |
| Shares Change (QoQ) | 0.94% | 0.27% |
| Float | 39,882,900 | 37,462,700 |
| Shares Held by Insiders | 11.4% | 10.5% |
| Shares Held by Institutions | 106.6% | 63.5% |
Scores
| Measure | Beta Bionics | Industry median |
|---|---|---|
| Altman Z-Score | 10.94 | 1.95 |
| Piotroski F-Score | 6 | 5 |
Calculated by StockData from Beta Bionics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.